Destiny Pharma plc D89.F Stock
Destiny Pharma plc Price Chart
Destiny Pharma plc D89.F Financial and Trading Overview
Destiny Pharma plc stock price | 0.11 EUR |
Previous Close | 0.36 EUR |
Open | 0.35 EUR |
Bid | 0.35 EUR x N/A |
Ask | 0.37 EUR x N/A |
Day's Range | 0.35 - 0.35 EUR |
52 Week Range | 0.32 - 0.79 EUR |
Volume | 100 EUR |
Avg. Volume | 0 EUR |
Market Cap | 33.62M EUR |
Beta (5Y Monthly) | 0.372796 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.07 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
D89.F Valuation Measures
Enterprise Value | 20.31M EUR |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 217.59532 |
Price/Book (mrq) | 3.3461537 |
Enterprise Value/Revenue | 131.484 |
Enterprise Value/EBITDA | -2.616 |
Trading Information
Destiny Pharma plc Stock Price History
Beta (5Y Monthly) | 0.372796 |
52-Week Change | -56.38% |
S&P500 52-Week Change | 20.43% |
52 Week High | 0.79 EUR |
52 Week Low | 0.32 EUR |
50-Day Moving Average | 0.41 EUR |
200-Day Moving Average | 0.57 EUR |
D89.F Share Statistics
Avg. Volume (3 month) | 0 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 95.26M |
Float | 57.36M |
Short Ratio | N/A |
% Held by Insiders | 18.85% |
% Held by Institutions | 19.49% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -5033.26% |
Gross Margin | 100.00% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -56.91% |
Return on Equity (ttm) | -85.93% |
Income Statement
Revenue (ttm) | 154.5K EUR |
Revenue Per Share (ttm) | 0.002 EUR |
Quarterly Revenue Growth (yoy) | 14.39% |
Gross Profit (ttm) | N/A |
EBITDA | -7764016 EUR |
Net Income Avi to Common (ttm) | -6503569 EUR |
Diluted EPS (ttm) | -0.11 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 4.9M EUR |
Total Cash Per Share (mrq) | 0.07 EUR |
Total Debt (mrq) | 0 EUR |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 5.565 |
Book Value Per Share (mrq) | 0.104 |
Cash Flow Statement
Operating Cash Flow (ttm) | -5892289 EUR |
Levered Free Cash Flow (ttm) | -4185202 EUR |
Profile of Destiny Pharma plc
Country | Germany |
State | N/A |
City | Brighton |
Address | Sussex Innovation Centre |
ZIP | BN1 9SB |
Phone | 44 1273 704440 |
Website | https://www.destinypharma.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 24 |
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Research/Biofilms that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, dermal, oral and ocular infections. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; Sebela Pharmaceuticals; the University of Southampton; Aston University; the University of Sheffield; National Biofilms Innovation Centre; National Institute of Allergy and Infectious Diseases; Cystic Fibrosis Foundation; Cardiff University; and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.
Q&A For Destiny Pharma plc Stock
What is a current D89.F stock price?
Destiny Pharma plc D89.F stock price today per share is 0.11 EUR.
How to purchase Destiny Pharma plc stock?
You can buy D89.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Destiny Pharma plc?
The stock symbol or ticker of Destiny Pharma plc is D89.F.
Which industry does the Destiny Pharma plc company belong to?
The Destiny Pharma plc industry is Biotechnology.
How many shares does Destiny Pharma plc have in circulation?
The max supply of Destiny Pharma plc shares is 99.2M.
What is Destiny Pharma plc Price to Earnings Ratio (PE Ratio)?
Destiny Pharma plc PE Ratio is now.
What was Destiny Pharma plc earnings per share over the trailing 12 months (TTM)?
Destiny Pharma plc EPS is -0.07 EUR over the trailing 12 months.
Which sector does the Destiny Pharma plc company belong to?
The Destiny Pharma plc sector is Healthcare.